FX-909（FX 909） is a first-in-class inverse agonist of the peroxisome proliferator-activated receptor gamma (PPARG) lineage transcription factor with EC50 of 1 nM and shows >2000-fold selectivity for PPARG over PPARA/PPARD - acting through a mechanism that promotes a repressive conformation of PPARG.

BAY-2965501 is a first-in-class a diacylglycerol kinase zeta (DGKζ, lipid kinase) inhibitor with IC50 of 27 nM/35 nM (human/mouse) and shows >20-fold selectivity for DGKζ over other DGK isotypes. BAY-2965501 blocks DGKζ in T-cells to activate them

ABBV-319 is a first-in-class glucocorticoid receptor modulator agonist ADC for B-cell malignancies

ARV-766 is an orally active and potent proteolysis targeting chimera (PROTAC) protein degrader. ARV-766 degrades wild-type androgen receptor (AR) but also relevant AR LBD mutants, including the most prevalent AR L702H, H875Y, and T878A mutations[1].

M3913 is an antitumor compound.

TNG260 is a CoREST-selective deacetylase inhibitor and shows 500-fold selectivity for the CoREST complex over the other HDAC1-containing complexes, NuRD and Sin3.

ZW251 is an antibody drug conjugate (ADC) consisting of a topoisomerase l inhibitor payload conjugated to an antibody targeting Glypican-3(GPC3).

MRT-2359 a potent, selective and orally bioavailable GSPT1-directed molecular glue degrader (MGD).

RMC-6291 is a potent covalent inhibitor of KRASG12C(ON) that forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA). RMC-6291 overcomes limitations of first-generation KRASG12C(OFF) inhibitors in preclinical models by directly targeting the active form of this important oncogenic driver.

DT-109 is a glycine-based tripeptide (Gly-Gly-Leu) that lowers steatohepatitis and hepatic fibrosis via induction of fatty acid (FA) degradation and antioxidant defense through de novo glutathione (GSH) biosynthesis.

Camlipixant (BLU-5937) a potent, selective, non-competitive and orally active P2X3 homotrimeric receptor antagonist with an IC50 of 25 nM against hP2X3 homotrimeric. Camlipixant shows potent anti-tussive effect and no taste alteration. Camlipixant can be used for the research of unexplained, refractory chronic cough.

UCM1306 is a potent and orally active human dopamine D1 receptor allosteric modulator (PAM). UCM-1306 increases the endogenous dopamine (DA) maximal effect both in human and mouse D1 receptors. UCM-1306 is not only for improving motor symptoms but also for addressing the key comorbid cognitive impairment associated with long-term Parkinson’s disease (PD).

MS023 hydrochloride is a potent, selective and cell-active inhibitor of human type I protein arginine methyltransferases (PRMT), with IC50 values of 30, 119, 83, 4 and 5 nM for PRMT1, PRMT3, PRMT4, PRMT6, and PRMT8, respectively.

SU056 is an inhibitor of Y box binding protein 1 (YB-1) with IC50 of 1.73 μM in Sk0V3 cells.

Usp22i-S02(USP22-IN-1, compound S02) is a potent inhibitor of ubiquitin specific peptidase 22 (USP22). It showed anticancer activity by suppressing Foxp3 expression in T-regulatory cells.

Zuranolone(SAGE-217, CS-2797) is an orally active and potent neuroactive steroid and positive allosteric modulator of the GABAA receptor, with EC50s of 296 nM for α1β2γ2 receptor.

LNP023 is a highly potent factor B (FB) inhibitor with an IC50 value of 10 nM. LNP023 shows direct, reversible, and high-affinity binding to human FB (KD=7.9 nM).

8-Azaadenosine is a potent ADAR1 inhibitor and an A-to-I editing inhibitor. 8-Azaadenosine blocks RNA editing and inhibits proliferation, 3D growth, invasion, and migration in thyroid cancer cells.

AL-A12 is an ionizable cationic amino lipid that has been used in the formation of lipid nanoparticles (LNPs).1 LNPs containing AL-A12 and encapsulating minicircle DNA that encodes for GFP have been used to induce GFP expression in Huh7 cells.

D-Lin-MC4-DMA(MC4) is a cationic lipid that has been synthesized for Lipid nanoparticles (LNPs) to deliver the siRNA.